Stem cell infusion for single-ventricle heart failure during surgery
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests whether an infusion of heart stem/progenitor cells can improve outcomes for children with a single working heart chamber (single ventricle) who are scheduled for the next surgical stage (Glenn or Fontan). It may help the heart function after surgery, but participation depends on several heart, lung, brain, and overall health safety criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a single-ventricle heart condition with heart failure, and surgery is planned (either Glenn stage 2 or Fontan stage 3)
- An ultrasound of the heart shows an ejection fraction (EF) of 55% or less
- A parent/guardian can sign consent in writing for the study
- No history of cardiogenic shock (life-threatening heart pumping failure)
- No life-threatening rhythm problems or severe uncontrollable irregular heartbeat
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gel called VentriGel, which is injected directly into the heart muscle during Glenn surgery to see if it is safe and helps children with hypoplastic left heart syndrome (HLHS). The study aims to improve heart function in babies who need this second-stage surgery.
This trial studies whether a newer “tissue-engineered” blood vessel graft is safe and works well in children who need a specific heart surgery connection outside the heart. It may help by offering a new type of graft, but your team will screen for size and medical factors first.
This trial tests a treatment made from stem cells that are turned into heart muscle cells and injected directly into the heart. It is for people with advanced heart failure who are already on the best available medicines and who are scheduled to have bypass surgery.
This trial tests a new treatment using heart muscle cells made from stem cells (iPSC-CMs) combined with either a heart pump (LVAD) or bypass surgery (CABG) for people with end-stage heart failure. The goal is to see if adding these cells can help the heart work better.
This trial tests whether injecting special cells (cell therapy) can help the heart recover in people with advanced heart failure who are getting a mechanical heart pump (LVAD). It may offer a new way to improve heart function and quality of life.
This trial tests whether stem cells from donated umbilical cord blood can improve heart function in people with heart failure caused by blocked arteries. You'll receive one or more infusions of these cells through a vein.
Hear when a new Hypoplastic Left Heart Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.